Journal article

Impact of Training Method on the Robustness of the Visual Assessment of F-18-Florbetaben PET Scans: Results from a Phase-3 Study

John Seibyl, Ana M Catafau, Henryk Barthel, Kenji Ishii, Christopher C Rowe, James B Leverenz, Bernardino Ghetti, James W Ironside, Masaki Takao, Hiroyasu Akatsu, Shigeo Murayama, Santiago Bullich, Andre Mueller, Norman Koglin, Walter J Schulz-Schaeffer, Anja Hoffmann, Marwan N Sabbagh, Andrew W Stephens, Osama Sabri

Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2016

Grants

Awarded by Grants-in-Aid for Scientific Research


Funding Acknowledgements

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. The trial was funded by Bayer Pharma AG, Berlin (Germany), and Piramal Imaging S.A., Matran (Switzerland). Medical writing support was provided by Dan Booth (Bioscript Medical, London, U.K.) and funded by Piramal Imaging S.A. John Seibyl holds equity interest in Molecular Neuroimaging and is a consultant to Piramal Imaging and GE Healthcare. Ana M. Catafau, Santi Bullich, Andrew W. Stephens, Andre Mueller, and Norman Koglin are employees of Piramal Imaging GmbH, Berlin, Germany. Henryk Barthel received consultant and speaker honoraria as well as travel expenses from Bayer Healthcare/Piramal Imaging. Kenji Ishii has been a paid consultant to GE Healthcare. Christopher C. Rowe has received research grants from Bayer Schering Pharma. James B. Leverenz is a consultant with Bayer, Citibank, Piramal Imaging, and Navidea Biopharmaceuticals. Bernardino Ghetti is a consultant with Piramal Imaging and has a contract with Eli Lilly and Company. James W. Ironside is a consultant with Piramal Imaging, Covance, U.K., and has received honoraria from Springer and McCann Healthcare. Work by Hiroyasu Akatsu was partially supported by funding from Bayer. Masaki Takao received a research grant from Bayer Health Care. Walter. J. Schulz-Schaeffer received research grants from Bayer HealthCare and Piramal Imaging. Marwan W. Sabbagh has contracts or grants with Bayer HealthCare, Piramal Imaging, Navidea Biopharmaceuticals, Avid, GE Healthcare, Avanir, Elan, Functional Neuromodulation, Eisai, Pfizer, and Genentech; is a consultant for Lilly, Avid, Piramal Imaging, Biogen, and Eisai; and receives royalties from Ten Speed and Wiley. Osama Sabri received consultant and speaker honoraria as well as travel expenses from Bayer Healthcare/Piramal Imaging. Anja Hoffmann is an employee of Bayer Pharma AG, Berlin, Germany. No other potential conflict of interest relevant to this article was reported.